AUSTIN, Texas, March 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that new adult repeat-dose data from its Phase 1/2 open-label study of pegzilarginase (AEB1102) in patients with Arginase 1 Deficiency will be reported in a poster presentation at the 2018 Annual Meeting of The Society for Inherited Metabolic Disorders in San Diego, California, March 11-14.
Abstracts are available online at www.simd.org/meetings/simd2018/. Details of the poster presentation are listed below.
Title: Once Weekly Intravenous Administration of Pegzilarginase Produces Marked and Sustained Reductions in Plasma Arginine Levels in Adults with Arginase 1 Deficiency: Early Results from a Phase 1/2 Open-Label Study of Pegzilarginase
Poster Number: 132
Lead Author: Roberto T. Zori, M.D., Professor, Department of Pediatrics, and Chief, Division of Genetics and Metabolism, at the University of Florida in Gainesville
Presentation Date: Monday, March 12, 7:30 p.m. to 10:00 p.m. PT
Location: Paradise Point Resort, San Diego, California
An electronic version of the poster will be available for download on the Presentations & Events section of the Company’s investor relations website after the conference.
Clinical Update Conference Call & Webcast Details
Aeglea will hold a clinical update conference call on Tuesday, March 13, 2018 at 8:00 a.m. ET. To access the live conference call via phone, please dial (877) 709-8155 (toll free) within the United States, or +1 (201) 689-8881 internationally. A replay of the call will be available through March 20, 2018 by dialing (877) 660-6853 within the United States or +1 (201) 612-7415 internationally. The conference ID is 13677425.
To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
About Pegzilarginase (AEB1102) in Arginase 1 Deficiency
Pegzilarginase is an enhanced human arginase that enzymatically degrades the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency, a debilitating urea cycle disorder caused by deficiency of a key arginine metabolizing enzyme that leads to severe and progressive hyperargininemia-related neurological abnormalities, hyperammonemia and early mortality. Pegzilarginase is intended for use as an enzyme replacement therapy in patients to reduce elevated blood arginine levels. The Company’s Phase 1 data demonstrated that pegzilarginase reduced blood arginine levels into the normal range, supporting its mechanism of action.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency and arginine dependent cancers, both as monotherapy and in combination with immune checkpoint inhibitors. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding the timing and success of our current and future preclinical and clinical trials, and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For more information, please visit: http://aegleabio.com.
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
investors@aegleabio.com
Media Contact:
David Calusdian
Sharon Merrill Associates
agle@investorrelations.com